obesity – Page 2

GLP-1 Receptor Agonists Significantly Reduce Atrial Fibrillation Recurrence and Mortality Following Catheter Ablation in Obese Patients

By MedXY 02/04/2026

This large-scale real-world analysis reveals that GLP-1 receptor agonist therapy reduces atrial fibrillation recurrence by 18% and lowers all-cause mortality in obese patients following catheter ablation, highlighting a potent upstream strategy for rhythm control.

Cardiology Diabetes & Endocrinology news

GLP-1 Receptor Agonists Associated with Lower Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients

By MedXY 02/04/2026

This real-world study demonstrates that GLP-1 receptor agonists significantly reduce AF recurrence, progression to permanent AF, and cardiovascular hospitalizations in obese patients following catheter ablation, highlighting their role as a critical adjunctive therapy in metabolic-arrhythmic management.

Diabetes & Endocrinology news Public Health

Challenging Public Health Dogma: Six Months of Low Sweet Taste Exposure Fails to Shift Preference or Weight

By MedXY 02/04/2026

The Sweet Tooth Trial reveals that reducing dietary sweet exposure for six months does not decrease sweet taste liking, calorie intake, or weight, questioning the efficacy of current public health strategies centered solely on reducing sweet-tasting food exposure.

Cardiology Diabetes & Endocrinology news

Beyond Weight Loss: CagriSema Emerges as a Potent Antihypertensive in Obesity Management

By MedXY 02/02/2026

The REDEFINE 1 trial demonstrates that CagriSema, a semaglutide/cagrilintide combination, significantly reduces blood pressure in adults with overweight or obesity, even among those with resistant hypertension, while facilitating the reduction of concomitant antihypertensive medications.

Cardiology news Psychiatry

Keto vs. Mediterranean: New Evidence on Which Diet Wins for Heart and Brain Health

By MedXY 01/20/2026

This article compares the Ketogenic and Mediterranean diets' impact on cardiovascular markers and mental health, highlighting results from two recent pilot studies on blood pressure and the gut-brain axis.

Clinical Updates Diabetes & Endocrinology news

Frontiers in Cardiometabolic Medicine: From Oral GLP-1 Small Molecules to RNAi Therapeutics

By MedXY 01/17/2026

This review synthesizes recent breakthroughs in obesity, type 2 diabetes, and lipidology, focusing on oral orforglipron, zodasiran for HoFH, and adolescent metabolic risk factors.

Diabetes & Endocrinology news Public Health

Weekly Semaglutide 2.4 mg Delivers 16% Weight Loss in Asian Adults with BMI ≥25: Results from the STEP 11 Phase 3 Trial

By MedXY 01/15/2026

The STEP 11 trial demonstrates that once-weekly semaglutide 2.4 mg significantly reduces bodyweight by 16% in Asian adults with obesity (BMI ≥25 kg/m2), providing robust evidence for population-specific clinical guidelines and reimbursement policies in South Korea and Thailand.

Diabetes & Endocrinology Gastroenterology news

Multiomics Outperform Phenotype in Predicting Post-Diet Weight Regain and Body Composition Dynamics

By MedXY 12/31/2025

A post hoc analysis of the LEAN-TIME trial reveals that integrating gut microbiome and metabolomic data with clinical phenotypes significantly improves the prediction of weight loss and regain, offering a framework for precision weight management and personalized obesity care.

Diabetes & Endocrinology Internal Medicine news

Tirzepatide Shows Unprecedented Weight Loss and Reduced Insulin Demand in Adults with Type 1 Diabetes and Obesity

By MedXY 12/30/2025

A Phase 2 trial demonstrates that tirzepatide significantly reduces body weight, HbA1c, and total daily insulin requirements in adults with type 1 diabetes and obesity, offering a promising therapeutic strategy for managing metabolic health in this population.

Critical Care Nephrology news Transplantation

Kidney Replacement Therapy Independently Predicts 90-Day Mortality in Critically Ill Patients with Obesity: A 15-Year Trend Analysis

By MedXY 12/30/2025

A 15-year cohort study reveals that obese ICU patients requiring kidney replacement therapy face nearly triple the mortality rate of those who do not, despite a declining trend in overall acute kidney injury incidence within this high-risk population.

Cardiology Internal Medicine news

Beyond Congestion: The Wet-Cold Phenotype Drives Mortality in Obese HFpEF

By MedXY 12/29/2025

A hemodynamic study of 227 HFpEF patients reveals that 34% exhibit a low-output phenotype. This cold status, especially when combined with congestion, significantly increases mortality risk in overweight and obese individuals, highlighting the need for precise hemodynamic profiling.

Anesthesiology Critical Care news

Norepinephrine at Extubation: Challenging the Hemodynamic Safety Paradigm in Critically Ill Patients with Obesity

By MedXY 12/28/2025

A multicenter validation study confirms that low-dose norepinephrine at the time of extubation does not increase reintubation rates in patients with obesity, offering clinicians greater flexibility in weaning strategies for hemodynamically fragile patients.

Cardiology Internal Medicine news

Rethinking Biomarker Thresholds: Why Current NT-proBNP Cutoffs Fail Patients with Obesity and HFpEF

By MedXY 12/26/2025

A pooled analysis of 14,750 patients reveals that current fixed NT-proBNP thresholds significantly underestimate cardiovascular risk in obese patients with heart failure, suggesting a critical need for BMI-adjusted diagnostic and trial eligibility cutoffs.

Cardiology Internal Medicine news

High BMI, High Benefit: How PCSK9 Inhibition Optimizes Outcomes in Obese Patients with ASCVD

By MedXY 12/25/2025

A prespecified analysis of the FOURIER trial reveals that patients with obesity and atherosclerotic cardiovascular disease experience significantly higher absolute and relative risk reductions with evolocumab, particularly those with a BMI above 35 kg/m2, emphasizing a targeted therapeutic advantage for this high-risk population.

Cardiology Diabetes & Endocrinology news

Beyond MACE: Semaglutide Significantly Reduces Hospitalization Burden in Patients with Obesity and Cardiovascular Disease

By MedXY 12/23/2025

This exploratory analysis of the SELECT trial demonstrates that semaglutide 2.4 mg reduces total hospital admissions and total days spent in the hospital by approximately 10-11% in patients with established cardiovascular disease and obesity, highlighting benefits beyond traditional major adverse cardiovascular events.

Cardiology Clinical Updates Diabetes & Endocrinology news

Diabetes, Obesity, and Early Rhythm Control in Atrial Fibrillation: Insights from the EAST-AFNET 4 Trial

By MedXY 12/22/2025

This analysis of the EAST-AFNET 4 trial highlights that early rhythm control therapy's cardiovascular benefits and safety are consistent regardless of diabetes or obesity status in atrial fibrillation patients.

Cardiology Diabetes & Endocrinology news

Tirzepatide Lowers 10‑Year Predicted Risk of Cardiovascular Disease and Type 2 Diabetes in Adults with Obesity and Prediabetes: Post hoc Analysis of SURMOUNT‑1

By MedXY 12/05/2025

A post hoc analysis of the three‑year SURMOUNT‑1 trial found that once‑weekly tirzepatide (5–15 mg) produced dose‑dependent reductions in 10‑year predicted risks for ASCVD, heart failure, total CVD and progression to type 2 diabetes versus placebo in adults with obesity and prediabetes.

Diabetes & Endocrinology news

Orforglipron in Type 2 Diabetes and Obesity: A Promising Oral GLP‑1 Agonist That Delivers Clinically Meaningful Weight and Glycaemic Benefits

By MedXY 11/28/2025

In ATTAIN‑2, oral orforglipron produced dose‑dependent, statistically superior weight loss and improved HbA1c versus placebo over 72 weeks in adults with overweight/obesity and type 2 diabetes, with an adverse‑event profile dominated by gastrointestinal effects.

news Oncology Urology

Metformin Fails to Delay Progression on Active Surveillance for Low‑Risk Prostate Cancer — Unexpected Signal in Obese Men

By MedXY 11/23/2025

The MAST phase III trial found no benefit of metformin (850 mg twice daily) versus placebo for delaying progression in men with low‑risk prostate cancer on active surveillance; a prespecified subgroup showed increased pathologic progression in obese patients.

news Oncology Urology

Metformin Does Not Delay Progression on Active Surveillance for Low‑Risk Prostate Cancer — Unexpected Signal in Obesity

By MedXY 11/23/2025

A randomized phase III trial (MAST) found metformin did not prolong progression‑free survival in men on active surveillance for low‑risk prostate cancer; an exploratory subgroup showed increased pathologic progression in obese patients.